The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes (MAXWEL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Soo Lim, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier:
NCT00816608
First received: December 31, 2008
Last updated: October 24, 2013
Last verified: October 2013
  Purpose

Hypothesis : The maximum body weight in lifetime is associated with the onset of development of type 2 diabetes.


Condition
Diabetes
Prediabetes

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of MAXimum Weight in Lifetime on Glucose Homeostasis (MAXWEL)

Resource links provided by NLM:


Further study details as provided by Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • The development of diabetes [ Time Frame: Five years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • DM complication [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 3000
Study Start Date: August 2006
Study Completion Date: September 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
type 2 diabetes

Detailed Description:

Obesity is well recognized risk factor for type 2 diabetes. Recent studies reported that weight change, especially severe weight gain was associated with an increased risk of type 2 diabetes. The aim of this study is to investigate whether the maximum body weight of lifetime is associated with the early onset of type 2 diabetes or an increased risk of type 2 diabetes in Korean.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Korean with type 2 diabetes Korean with confirmed IFG or IGT Korean with NGT

Criteria

Inclusion Criteria:

  • Korean with type 2 diabetes
  • Korean with confirmed IFG or IGT
  • Korean with NGT

Exclusion Criteria:

  • Malignancy except thyroid cancer
  • Active tuberculosis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00816608

Locations
Korea, Republic of
Seoul National University Bundang Hospital
Seongnam, Bundang-gu, Korea, Republic of, 463-707
Sponsors and Collaborators
Seoul National University Bundang Hospital
Investigators
Principal Investigator: Soo Lim Seoul National University Bundang Hospital
  More Information

No publications provided

Responsible Party: Soo Lim, Professor, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT00816608     History of Changes
Other Study ID Numbers: MAXWEL 09
Study First Received: December 31, 2008
Last Updated: October 24, 2013
Health Authority: Korea: Food and Drug Administration

Keywords provided by Seoul National University Bundang Hospital:
diabetes
prediabetes
impaired fasting glucose (IFG)
impaired glucose tolerance (IGT)
body weight

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Prediabetic State
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperglycemia

ClinicalTrials.gov processed this record on April 15, 2014